Table 1.
Correlation between clinicopathological factors and GPER expression in patients with HCC.
| Characteristics | Patients (%) | GPER expression | P value | |
|---|---|---|---|---|
| Negative Positive | ||||
| Total | 141 (100) | 41 (29.1%) | 141 (70.9%) | |
| Sex | 0.043 | |||
| Male | 126 (89.4) | 40 (31.7%) | 86 (68.3%) | |
| Female | 15 (10.6) | 1 (6.7%) | 14 (93.3%) | |
| Age | 0.415 | |||
| <50 | 75 (53.2) | 24 (32.0%) | 51 (68.0%) | |
| ≧50 | 66 (46.8) | 17 (25.8%) | 49 (74.2%) | |
| HBsAg | 0.036 | |||
| Negative | 18 (12.8) | 9 (50.0%) | 9 (50.0%) | |
| Positive | 123 (87.2) | 32 (26.0%) | 91 (74.0%) | |
| Node Status | 0.430 | |||
| Negative | 131 (92.9) | 37 (28.2%) | 94 (71.8%) | |
| Positive | 10 (7.1) | 4 (40.0%) | 6 (60.0%) | |
| Tumor size | 0.002 | |||
| T (<5 cm) | 80 (56.7) | 15 (18.8%) | 65 (81.2%) | |
| T (≧5 cm) | 61 (43.3) | 26 (42.6%) | 35 (57.4%) | |
| LDH | 0.085 | |||
| <225 U/L | 71 (50.4) | 16 (22.5%) | 55 (77.5%) | |
| ≧225 U/L | 70 (49.6) | 25 (35.7%) | 45 (64.3%) | |
| AFP | 0.014 | |||
| ≦400 ng/ml | 81 (57.4) | 17 (21.0%) | 64 (79.0%) | |
| >400 ng/ml | 60 (42.6) | 24 (40.0%) | 36 (60.0%) | |
| Cancer embolus | 0.751 | |||
| Negative | 124 (87.9) | 35 (28.2%) | 89 (71.8%) | |
| Positive | 17 (12.1) | 6 (35.3%) | 11 (64.7%) | |
| Hepatocirrhosis | 0.511 | |||
| Negative | 112 (70.4) | 34 (30.4%) | 78 (69.6%) | |
| Positive | 29 (20.6) | 7 (24.1%) | 22 (75.9%) | |
| Clinical stage | 0.402 | |||
| I-II | 90 (63.8) | 24 (26.7%) | 66 (73.3%) | |
| III-IV | 51 (36.2) | 17 (33.3%) | 34 (66.7%) | |
P values <0.05 in bold were considered to be statistically significant.